According to a February 25 press release, Amondys 45 (casimersen), a therapeutic option for patients with Duchenne muscular dystrophy (DMD), recently became FDA-approved. The therapy
On February 18, 2021, specialty pharmaceutical company Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) shared that a Phase 2 clinical trial evaluating KHK4083 had reached its
According to BioSpace, Biohaven Pharma has utilized their MATE platform to create and develop a hyperimmune globulin mimic (HGM) that is able to both bind
Billions of dollars have been spent in research over decades, resulting in only two therapies that treat symptoms of Alzheimer’s disease (AD). There are no
In some cases, elderly patients (those over 70 years old) with esophageal cancer have been told that surgery is not the best option. This
According to a story from epmmagazine.com, a team of researchers from the Universities of Exeter and Nottingham have recently completely a study that could lead
© Copyright Patient Worthy
